


09/284, 424




RN 206864-17-7 CAPLUS

CN L-Alaninamide,


N-[(phenylmethoxy) carbonyl]-L-valyl-N-[1-(carboxymethyl)-2-oxo-3-(1-oxo-3,3-diphenylpropoxy)propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206864-18-8 CAPLUS


CN 1-Naphthaleneacetic acid, 4-carboxy-3-[[3-methyl-1-oxo-2-[(phenylmethoxy) carbonyl]amino]butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)



RN 206864-19-9 CAPLUS

CN L-Valinamide, N-[(phenylmethoxy)carbonyl]-L-.alpha.-glutamyl-N-[1-(carboxymethyl)-2-oxo-3-[1-oxo-3-phenyl-2-(phenylmethyl)propoxy]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206864-20-2 CAPLUS

CN L-Alaninamide,
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-2-oxo-3-[1-oxo-3-phenyl-2-(phenylmethyl)propoxy]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206864-21-3 CAPLUS

CN L-Valinamide,
N-acetyl-L-tyrosyl-L-.alpha.-glutamyl-N-[1-(carboxymethyl)-2-oxo-3-[1-oxo-3-phenyl-2-(phenylmethyl)propoxy]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206864-22-4 CAPLUS

CN L-Valinamide, N-(1-oxo-3-phenylpropyl)-L-.alpha.-glutamyl-N-[1-(carboxymethyl)-2-oxo-3-[1-oxo-3-phenyl-2-(phenylmethyl)propoxy]propyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206864-23-5 CAPLUS

CN L-Valinamide, N-(1-oxo-3-phenylpropyl)-L-.alpha.-glutamyl-N-[1-(carboxymethyl)-3-[(1-naphthalenylacetyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 206864-24-6 CAPLUS


09/284, 424

CN Benzenepropanoic acid, .beta.-phenyl-, 4-carboxy-3-[(3-methyl-1-oxo-2-[(phenylmethoxy)carbonyl]amino)butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 206864-25-7 CAPLUS

CN 1-Naphthaleneacetic acid,
3-[(2-(acetylamino)-3-hydroxy-1-oxobutyl]amino]-
4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)



RN 206864-26-8 CAPLUS


CN Benzenepropanoic acid, .beta.-phenyl-, 3-[(2-(acetylamino)-3-hydroxy-1-oxobutyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)




RN 206864-27-9 CAPLUS

CN L-Valinamide, N-acetyl-L-tryptophyl-L-.alpha.-glutamyl-N-[1-(carboxymethyl)-2-oxo-3-[1-oxo-3-phenyl-2-(phenylmethyl)propoxy]propyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 206864-28-0 CAPLUS


CN Benzenepropanoic acid, .beta.-phenyl-,
4-carboxy-2-oxo-3-[(1-oxo-2-[(1-oxo-
4-phenylbutyl)amino]propyl)amino]butyl ester (9CI) (CA INDEX NAME)


RN 206864-29-1 CAPLUS

CN L-Valinamide, N-acetyl-L-tryptophyl-L-.alpha.-glutamyl-N-[1-
(carboxymethyl)-3-[(1-naphthalenylacetyl)oxy]-2-oxopropyl]- (9CI) (CA
INDEX NAME)

Absolute stereochemistry.

PAGE 1-A






RN 206864-30-4 CAPLUS

CN L-Valinamide, N-acetyl-L-.alpha.-glutamyl-N-[1-(carboxymethyl)-3-[(1-naphthalenylacetyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.




RN 206864-31-5 CAPLUS

CN L-Valinamide,
N-acetyl-L-tyrosyl-L-.alpha.-glutamyl-N-[1-(carboxymethyl)-3-[(1-naphthalenylacetyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.






L4 ANSWER 8 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1998:183935 CAPLUS
 DOCUMENT NUMBER: 128:244345
 TITLE: Preparation of N-substituted-2-indolyl dipeptides as
 inhibitors of the ICE/ced-3 family of cysteine
 proteases
 INVENTOR(S): Karanewsky, Donald S.; Bai, Xu
 PATENT ASSIGNEE(S): Idun Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 104 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9811129	A1	19980319	WO 1997-US16157	19970912
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5869519	A	19990209	US 1996-767175	19961216
AU 9744138	A1	19980402	AU 1997-44138	19970912
CN 1207101	A	19990203	CN 1997-191612	19970912
EP 920444	A1	19990609	EP 1997-942441	19970912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			US 1996-26011	19960912
			US 1996-767175	19961216
			WO 1997-US16157	19970912
OTHER SOURCE(S):	MARPAT 128:244345			
IT 204919-40-4P	RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)			
	(prepn. of substituted indolyl dipeptides as inhibitors of the			

ICE/ced-3 family of cysteine proteases)
 RN 204919-40-4 CAPLUS
 CN Benzoic acid, 2,6-dichloro-,
 4-carboxy-3-[(2S)-2-[(1,3-dimethyl-1H-indol-
 2-yl)carbonyl]amino]-3-methyl-1-oxobutyl]amino]-2-oxobutyl ester (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




L4 ANSWER 9 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1998:180773 CAPLUS
 DOCUMENT NUMBER: 128:242906
 TITLE: Inhibition of apoptosis using interleukin-1.betabeta.-converting enzyme (ice)/ced-3 family inhibitors
 INVENTOR(S): Fritz, Lawrence C.; Tomaselli, Kevin J.
 PATENT ASSIGNEE(S): Idun Pharmaceuticals, Inc., USA
 SOURCE: PCT Int. Appl., 184 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9810778	A1	19980319	WO 1997-US16369	19970912
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5869519	A	19990209	US 1996-767175	19961216
AU 9744819	A1	19980402	AU 1997-44819	19970912
CN 1207101	A	19990203	CN 1997-191612	19970912
EP 929311	A1	19990721	EP 1997-943323	19970912
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRIORITY APPLN. INFO.:			US 1996-26011	19960912
			US 1996-710621	19960920
			US 1996-767175	19961216
			WO 1997-US16369	19970912

OTHER SOURCE(S): MARPAT 128:242906
 IT 205036-44-8P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (inhibition of apoptosis using indolecarbonylamino acid amide ICE inhibitors)
 RN 205036-44-8 CAPLUS
 CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[[[(1,3-dimethyl-1H-indol-2-yl)carbonyl]amino]-3-methyl-1-oxobutyl]amino]-2-oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 10 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1998:77165 CAPLUS
 DOCUMENT NUMBER: 128:267567
 Correction of: 128:7521
 TITLE: Docking of a series of peptide-based interleukin-1.beta. converting enzyme inhibitors with aspartyl hemiacetals, .alpha.-((2,6-dichlorobenzoyl)oxy)methyl and (acyloxy)methyl ketone moieties
 AUTHOR(S): Hariprasad, Vankayalapati; Kulkarni, Vithal M.
 CORPORATE SOURCE: Pharmaceutical Division, University of Mumbai, Mumbai,
 SOURCE: 400019, India
 SOURCE: J. Mol. Model. (1997), 3(10), 443-454
 CODEN: JMMOFK; ISSN: 0948-5023
 URL:
<http://link.springer.de/link/service/journals/00894/bibs/7003010/70030443.htm>
 PUBLISHER: Journal of Molecular Modeling
 DOCUMENT TYPE: Journal; (online computer file)
 LANGUAGE: English
 IT 151272-16-1 151272-17-2 151594-01-3
 153088-74-5 154674-81-4 154674-82-5
 154674-84-7 154674-86-9 205324-40-9
 205324-41-0
 RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); PRP (Properties); BIOL (Biological study); PROC (Process) (docking anal. of peptide-based interleukin-1.beta. converting enzyme inhibitors)
 RN 151272-16-1 CAPLUS

CN L-Alaninamide, N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-3-[(2,6-bis(trifluoromethyl)benzoyl)oxy]-1-(carboxymethyl)-2-oxopropyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 151272-17-2 CAPLUS

CN L-Alaninamide, N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-3-(benzoyloxy)-1-(carboxymethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 151594-01-3 CAPLUS

CN L-Alaninamide,
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153088-74-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[(2S)-3-methyl-1-oxo-2-[(phenylmethoxy)carbonyl]amino]butyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 154674-81-4 CAPLUS

CN L-Alaninamide, N-acetyl-L-tyrosyl-L-valyl-N-[(1S)-1-(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B


—OH

RN 154674-82-5 CAPLUS

CN L-Alaninamide, N-acetyl-L-tyrosyl-L-valyl-N-[(1S)-3-[(2,6-bis(trifluoromethyl)benzoyl)oxy]-1-(carboxymethyl)-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B

~~OH


RN 154674-84-7 CAPLUS
 CN L-Alaninamide,
 N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-
 3-[(2,6-dihydroxybenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 154674-86-9 CAPLUS
 CN L-Alaninamide,
 N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-
 3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205324-40-9 CAPLUS

CN L-Alaninamide,
N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-
3-[(3-fluorobenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 205324-41-0 CAPLUS

CN L-Alaninamide,
N-(1-oxo-3-phenylpropyl)-L-valyl-N-[(1S)-1-(carboxymethyl)-
3-[(4-nitrobenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



TITLE: Preparation of tripeptide analogs containing benzoxazepine derivatives as cysteine protease inhibitors
 INVENTOR(S): Watanabe, Hiroyuki; Kamata, Shin; Fukuda, Tsunehiko
 PATENT ASSIGNEE(S): Takeda Chemical Industries, Ltd., Japan
 SOURCE: Jpn. Kokai Tokkyo Koho, 28 pp.
 CODEN: JKXXAF
 DOCUMENT TYPE: Patent
 LANGUAGE: Japanese
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 09295996	A2	19971118	JP 1997-50119	19970305
PRIORITY APPLN. INFO.:			JP 1996-49177	19960306
OTHER SOURCE(S):		MARPAT 128:35022		
IT 199613-81-5P RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of tripeptide analogs contg. benzoxazepine derivs. as cysteine protease and interleukin-1.beta. converting enzyme inhibitors for disease treatment)				
RN	199613-81-5	CAPLUS		
CN	Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[2-[3,4-dihydro-3-[(2-naphthalenylcarbonyl)amino]-4-oxo-1,5-benzoxazepin-5(2H)-yl]-1-oxopropyl]amino]-2-oxobutyl ester, [3S-[3R*,5(R*)]]-[partial]- (9CI) (CA INDEX NAME)			

Absolute stereochemistry.




L4 ANSWER 12 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1997:636190 CAPLUS
 DOCUMENT NUMBER: 127:307394
 TITLE: Preparation of N-(6-oxo-1-pyrimidinylacetyl)aspartic acid analogs as interleukin-1.beta.-converting enzyme inhibitors
 INVENTOR(S): Dolle, Roland E.; Prouty, Catherine P.; Chaturvedula,

PATENT ASSIGNEE(S): Prasad V.; Schmidt, Stanley J.
 SOURCE: Sanoft, Fr.
 U.S., 12 pp. Cont.-in-part of U.S. Ser. No. 221,712.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5670494	A	19970923	US 1995-559870	19951120
CA 2186511	AA	19951012	CA 1995-2186511	19950329
CN 1149292	A	19970507	CN 1995-193258	19950329
HU 75715	A2	19970528	HU 1996-2664	19950329
PRIORITY APPLN. INFO.:			US 1994-221712	19940331
OTHER SOURCE(S):		MARPAT 127:307394		
IT 173305-25-4P	173305-26-5P	173305-41-4P	RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (prepn. of N-(6-oxo-1-pyrimidinylacetyl)aspartic acid analogs as interleukin-1. β -converting enzyme inhibitors)	
RN 173305-25-4	CAPLUS			
CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[[[2-(4-fluorophenyl)-6-oxo- 5-[(phenylmethoxy)carbonyl]amino]-1(6H)-pyrimidinyl]acetyl]amino]-2- oxobutyl ester (9CI) (CA INDEX NAME)				

Absolute stereochemistry.



RN 173305-26-5 CAPLUS
 CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[[2-(4-fluorophenyl)-5-[(4-(methylthio)benzoyl]amino]-6-oxo-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 173305-41-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[6-oxo-5-[(phenylmethoxy)carbonyl]amino]-2-(2-thienyl)-1(6H)-pyrimidinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 13 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1997:541852 CAPLUS

DOCUMENT NUMBER: 127:234612

TITLE: Preparation of heterocyclyl aspartaldehyde peptide derivatives as interleukin-1. beta. converting enzyme inhibitors

INVENTOR(S): Bemis, Guy W.; Golec, Julian M. C.; Lauffer, David J.;

Mullican, Michael D.; Murcko, Mark A.; Livingston, David J.

PATENT ASSIGNEE(S): Vertex Pharmaceuticals, Inc., USA

SOURCE: U.S., 67 pp. Cont.-in-part of U.S. Ser. No. 261,452.
 CODEN: USXXAM
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 3
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5656627	A	19970812	US 1995-405581	19950317
US 5756466	A	19980526	US 1994-261452	19940617
US 5847135	A	19981208	US 1995-440898	19950525
US 5716929	A	19980210	US 1995-464964	19950605
ZA 9504988	A	19961217	ZA 1995-4988	19950615
WO 9535308	A1	19951228	WO 1995-US7617	19950616
W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD, MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT				
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2192089	AA	19951228	CA 1995-2192089	19950616
AU 9529446	A1	19960115	AU 1995-29446	19950616
EP 784628	A1	19970723	EP 1995-925257	19950616
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,				
SE				
CN 1159196	A	19970910	CN 1995-194381	19950616
BR 9508051	A	19971021	BR 1995-8051	19950616
HU 76622	A2	19971028	HU 1996-3475	19950616
JP 10504285	T2	19980428	JP 1995-502478	19950616
NO 9605365	A	19970217	NO 1996-5365	19961213
FI 9605036	A	19970214	FI 1996-5036	19961216
PRIORITY APPLN. INFO.:				
			US 1994-261452	19940617
			US 1995-405581	19950317
			US 1995-440898	19950525
			WO 1995-US7617	19950616

OTHER SOURCE(S): MARPAT 127:234612

IT 175209-21-9P 175209-22-OP


RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(prepn. of heterocycll aspartaldehyde peptide derivs. as interleukin-1.beta. converting enzyme inhibitors)

RN 175209-21-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[[2-oxo-3-[(phenylmethoxy)carbonyl]amino]-1(2H)-pyridinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 175209-22-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(phenylmethyl)-1(2H)-pyridinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



L4 ANSWER 14 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1997:502830 CAPLUS

DOCUMENT NUMBER: 127:122000

TITLE: Inhibitors of interleukin-1. β . converting enzyme
Batchelor, Mark J.; Bebbington, David; Bemis, Guy W.;
Fridman, Wolf Herman; Gillespie, Roger J.; Golec,
Julian M. C.; Gu, Yong; Lauffer, David J.;

INVENTOR(S): Livingston,

David J.; Matharu, Saroop S.; Mullican, Michael D.;
Murcko, Mark A.; Murdoch, Robert; Nyce, Philip L.;
Robidoux, Andrea L. C.; et al.

PATENT ASSIGNEE(S): USA

SOURCE: PCT Int. Appl., 946 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----
WO 9722619	A2	19970626	WO 1996-US20843	19961220

WO 9722619 A3 19971016
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,
 DK, EE, ES, FI, GB, GE, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT,
 RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR,
 IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML,
 MR, NE, SN, TD, TG
 US 5874424 A 19990223 US 1996-598332 19960208
 AU 9715222 A1 19970714 AU 1997-15222 19961220
 EP 869967 A2 19981014 EP 1996-945318 19961220
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO
 NO 9802597 A 19980812 NO 1998-2597 19980605
 PRIORITY APPLN. INFO.: US 1995-575641 19951220
 US 1996-598332 19960208
 US 1996-712878 19960912
 US 1996-31495 19961126
 US 1996-761483 19961206
 WO 1996-US20843 19961220

OTHER SOURCE(S): MARPAT 127:122000

IT 175209-83-3P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (inhibitors of interleukin-1.beta. converting enzyme)
 RN 175209-83-3 CAPLUS
 CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[([(3S)-2,3,4,5-
 tetrahydro-2-oxo-5-(1-oxo-3-phenylpropyl)-3-[(1-oxo-3-phenylpropyl)amino]-
 1H-1,5-benzodiazepin-1-yl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 175209-21-9P 175209-22-0P 192757-64-5P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (inhibitors of interleukin-1.beta. converting enzyme)

RN 175209-21-9 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[2-oxo-3-[(phenylmethoxy)carbonyl]amino]-1(2H)-pyridinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 175209-22-0 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-2-oxo-3-[[2-oxo-3-[(1-oxo-3-phenylpropyl)amino]-6-(phenylmethyl)-1(2H)-pyridinyl]acetyl]amino]butyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry. Rotation (-).



RN 192757-64-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-3-[[[(3S)-3-(benzoylamino)-2,3,4,5-tetrahydro-5-(methylsulfonyl)-2-oxo-1H-1,5-benzodiazepin-1-yl]acetyl]amino]-4-carboxy-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 15 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1997:397284 CAPLUS

DOCUMENT NUMBER: 127:44456

TITLE: Pyridazinodiazepines as a High-Affinity, P2-P3 Peptidomimetic Class of

Interleukin-1. β -Converting

Enzyme Inhibitor

AUTHOR(S): Dolle, Roland E.; Prasad, C. V. C.; Prouty, Catherine P.; Salvino, Joseph M.; Awad, Mohamed M. A.; Schmidt, Stanley J.; Hoyer, Denton; Ross, Tina Morgan; Graybill, Todd L.; Speier, Gary J.; Uhl, Joanne; Miller, Robert; Helaszek, Carla T.; Ator, Mark A.

CORPORATE SOURCE: Sanofi Winthrop Inc., Collegeville, PA, 19426, USA

SOURCE: J. Med. Chem. (1997), 40(13), 1941-1946

CODEN: JMCMAR; ISSN: 0022-2623

PUBLISHER: American Chemical Society

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 173305-25-4P 191212-33-6P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(pyridazinodiazepines as a high-affinity, P2-P3 peptidomimetic class of interleukin-1. β -converting enzyme inhibitor)

RN 173305-25-4 CAPLUS

CN Benzoic acid, 2,6-dichloro-,
(3S)-4-carboxy-3-[[[2-(4-fluorophenyl)-6-oxo-5-[(phenylmethoxy)carbonyl]amino]-1(6H)-pyrimidinyl]acetyl]amino]-2-oxobutyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 191212-33-6 CAPLUS

CN Benzoic acid, 2,6-dichloro-, 4-carboxy-3-[[3,4-dihydro-4-oxo-3-
[(phenylmethoxy)carbonyl]amino]-1,5-benzoxazepin-5(2H)-yl]acetyl]amino]-2-
oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 16 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1997:349500 CAPLUS

DOCUMENT NUMBER: 127:80118

TITLE: T-cell receptor ligation by peptide/MHC induces
activation of a caspase in immature thymocytes: the
molecular basis of negative selection

AUTHOR(S): Clayton, Linda K.; Ghendler, Yoseph; Mizoguchi,

Emiko;

Patch, Raymond J.; Ocain, Timothy D.; Orth, Kim;

Bhan,

CORPORATE SOURCE: Atul K.; Dixit, Vishva M.; Reinherz, Ellis L.
 Laboratory of Immunobiology, Dana-Farber Cancer
 Institute, Harvard Medical School, Boston, MA, 02115,
 USA

SOURCE: EMBO J. (1997), 16(9), 2282-2293
 CODEN: EMJODG; ISSN: 0261-4189

PUBLISHER: Oxford University Press

DOCUMENT TYPE: Journal

LANGUAGE: English


IT 191666-52-1P
 RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
 (prep. and biol. activity of)

RN 191666-52-1 CAPLUS


CN L-Valinamide,
 N-[5-[(3aS,6aR)-hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl]-1-oxopentyl]-L-.alpha.-aspartyl-L-.alpha.-glutamyl-N-[(1S)-1-(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 1-B



L4 ANSWER 17 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1997:199607 CAPLUS
 DOCUMENT NUMBER: 126:289777
 TITLE: Actin cleavage by CPP-32/apopain during the development of apoptosis
 AUTHOR(S): Mashima, Tetsuo; Naito, Mikihiko; Noguchi, Kohji;

CORPORATE SOURCE: Miller, Douglas K.; Nicholson, Donald W.; Tsuruo, Takashi
 Laboratory of Biomedical Research, Institute of Molecular and Cellular Biosciences, University of Tokyo, Tokyo, 113, Japan
 SOURCE: Oncogene (1997), 14(9), 1007-1012
 CODEN: ONCNES; ISSN: 0950-9232
 PUBLISHER: Stockton
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 189176-81-6
 RL: BAC (Biological activity or effector, except adverse); BIOL (Biological study)
 (apopain inhibited by; actin cleavage by CPP-32/apopain during the development of apoptosis)
 RN 189176-81-6 CAPLUS
 CN L-Valinamide, N-[(phenylmethoxy)carbonyl]-L-.alpha.-glutamyl-N-[(1S)-1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



L4 ANSWER 18 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1997:171652 CAPLUS
 DOCUMENT NUMBER: 126:233538
 TITLE: An ICE inhibitor, z-VAD-DCB attenuates ischemic brain damage in the rat
 AUTHOR(S): Loddick, Sarah A.; Mackenzie, Andrew; Rothwell, Nancy J.
 CORPORATE SOURCE: School of Biological Sciences 1.124, University of Manchester, Manchester, M13 9PT, UK
 SOURCE: NeuroReport (1996), 7(9), 1465-1468
 CODEN: NERPEZ; ISSN: 0959-4965
 PUBLISHER: Rapid Science Publishers
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 151594-01-3
 RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (ICE inhibitor z-VAD-DCB attenuates ischemic brain damage)
 RN 151594-01-3 CAPLUS
 CN L-Alaninamide,
 N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-


[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 19 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1997:56319 CAPLUS
 DOCUMENT NUMBER: 126:166088
 TITLE: .alpha.-[(Tetronoyl)oxy]- and .alpha.-[(tetramoyl)oxy]methyl ketone inhibitors of the interleukin-1.beta. converting enzyme (ICE)
 AUTHOR(S): Graybill, Todd L.; Prouty, Catherine P.; Speier, Gary J.; Hoyer, Denton; Dolle, Ronald E.; Helaszek, Carla T.; Ator, Mark A.; Uhl, Joanne; Strasters, Joost
 CORPORATE SOURCE: Sanofi Winthrop Inc., Malvern, PA, 19355, USA
 SOURCE: Bioorg. Med. Chem. Lett. (1997), 7(1), 41-46
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 IT 187164-54-1P 187164-55-2P 187164-56-3P
 187164-57-4P
 RL: BAC (Biological activity or effector, except adverse); PNU (Preparation, unclassified); PRP (Properties); BIOL (Biological study); PREP (Preparation)
 (prepn. and structure of .alpha.-[(tetronoyl)oxy]- and .alpha.-[(tetramoyl)oxy]methyl ketones as inhibitors of interleukin-1.beta. converting enzyme)
 RN 187164-54-1 CAPLUS
 CN 3-Furancarboxylic acid, 2,5-dihydro-5-oxo-4-phenyl-, 4-carboxy-3-[(3-methyl-1-oxo-2-[(phenylmethoxy)carbonyl]amino]butyl]amino]-2-oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187164-55-2 CAPLUS

CN 3-Furancarboxylic acid, 2,5-dihydro-5-oxo-4-(phenylmethyl)-,

4-carboxy-3-[(3-methyl-1-oxo-2-[(phenylmethoxy)carbonyl]amino)butyl]amino]-2-oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 187164-56-3 CAPLUS

CN 1H-Pyrrole-3-carboxylic acid, 2,5-dihydro-5-oxo-4-phenyl-,

4-carboxy-3-[(3-methyl-1-oxo-2-[(phenylmethoxy)carbonyl]amino)butyl]amino]-2-oxobutyl ester, [S-(R*,R*)]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 187164-57-4 CAPLUS

CN L-Alaninamide, N-[(phenylmethoxy)carbonyl]-L-valyl-N-[(1S)-1-(carboxymethyl)-3-[[2,5-dihydro-5-oxo-4-(phenylmethyl)-3-furanyl]carbonyloxy]-2-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




IT 151594-01-3 153088-74-5

RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
(prepn. and structure of .alpha.-[(tetronoyl)oxy]- and .alpha.-[(tetramoyl)oxy]methyl ketones as inhibitors of interleukin-1. beta. converting enzyme)

RN 151594-01-3 CAPLUS

CN L-Alaninamide,
N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 153088-74-5 CAPLUS

CN Benzoic acid, 2,6-dichloro-, (3S)-4-carboxy-3-[(2S)-3-methyl-1-oxo-2-[(phenylmethoxy)carbonyl]amino]butylamino]-2-oxobutyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 20 OF 36 CAPLUS COPYRIGHT 1999 ACS

ACCESSION NUMBER: 1996:498709 CAPLUS

DOCUMENT NUMBER: 125:161791

TITLE: Cleavage of lamin A by Mch2.alpha. but not CPP32: multiple interleukin 1.beta.-converting

enzyme-related

proteases with distinct substrate recognition properties are active in apoptosis

AUTHOR(S): Takahashi, Atsushi; Alnemri, Emad S.; Lazebnik, Yuri A.; Fernandes-Alnemri, Teresa; Litwack, Gerald; Moir, Robert D.; Goldman, Robert D.; Poirier, Guy G.; Kaufmann, Scott H.; Earnshaw, William C.

CORPORATE SOURCE: Department Cell Biology and Anatomy, Johns Hopkins School Medicine, Baltimore, MD, 21205, USA

SOURCE: Proc. Natl. Acad. Sci. U. S. A. (1996), 93(16), 8395-8400

CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE: Journal
LANGUAGE: English


IT 154719-25-2

RL: NUU (Nonbiological use, unclassified); USES (Uses)
(cleavage of lamin A by Mch2.alpha. but not CPP32: multiple interleukin 1.beta.-converting enzyme-related proteases with distinct substrate recognition properties are active in apoptosis)


RN 154719-25-2 CAPLUS

CN L-Lysinamide, N-acetyl-L-tyrosyl-L-valyl-N-[1-(carboxymethyl)-3-[(2,6-dimethylbenzoyl)oxy]-2-oxopropyl]-N6-[5-(hexahydro-2-oxo-1H-thieno[3,4-d]imidazol-4-yl)-1-oxopentyl]-, [3aS-[3a.alpha.,4.beta.(R*),6a.alpha.]]- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 2-A



L4 ANSWER 21 OF 36 CAPLUS COPYRIGHT 1999 ACS
 ACCESSION NUMBER: 1996:326451 CAPLUS
 DOCUMENT NUMBER: 125:48346
 TITLE: First Examples of Peptidomimetic Inhibitors of

AUTHOR(S): Interleukin-1.beta. Converting Enzyme
 Dolle, Roland E.; Prouty, Catherine P.; Prasad, C. V.
 C.; Cook, Ewell; Saha, Ashis; Ross, Tina Morgan;
 Salvino, Joseph M.; Helaszek, Carla T.; Ator, Mark A.
 CORPORATE SOURCE: Sanofi Winthrop Inc., Collegeville, PA, 19426, USA
 SOURCE: J. Med. Chem. (1996), 39(13), 2438-2440
 CODEN: JMCMAR; ISSN: 0022-2623

DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 125:48346

IT 151594-01-3


RL: BAC (Biological activity or effector, except adverse); PRP
 (Properties); BIOL (Biological study)
 (prep. of peptidomimetic inhibitors of interleukin-1.beta. converting
 enzyme in relation to structure)

RN 151594-01-3 CAPLUS

CN L-Alaninamide,

N-[(phenylmethoxy)carbonyl]-L-valyl-N-[1-(carboxymethyl)-3-
 [(2,6-dichlorobenzoyl)oxy]-2-oxopropyl]-, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 177742-22-2P 177742-23-3P 177742-24-4P
 177742-25-5P 177742-26-6P 177742-27-7P
 177742-28-8P

RL: BAC (Biological activity or effector, except adverse); PRP
 (Properties); SPN (Synthetic preparation); BIOL (Biological study); PREP
 (Preparation)
 (prep. of peptidomimetic inhibitors of interleukin-1.beta. converting
 enzyme in relation to structure)

RN 177742-22-2 CAPLUS

CN Benzoic acid, 2,4-dichloro-, 4-carboxy-3-[[[2-(4-fluorophenyl)-6-oxo-5-
 [(phenylmethoxy)carbonyl]amino]-1(6H)-pyrimidinyl]acetyl]amino]-2-
 oxobutyl ester, (S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.